Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169780	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2023 (1 year, 1 month from now)
US7754731	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Mar, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2022 (2 months from now)
US7217713	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2022 (2 months from now)
US7217713 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2023 (7 months from now)
US7435734 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2023 (7 months from now)
US7169780 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2024 (1 year, 7 months from now)
US7754731 (Pediatric)	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Sep, 2029 (7 years from now)
US9649311	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Oct, 2030 (8 years from now)
US9649311 (Pediatric)	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Apr, 2031 (8 years from now)
US10772888	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Mar, 2032 (9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription